BG
DGX icon

Bahl & Gaynor’s Quest Diagnostics DGX Stock Holding History

Bahl & Gaynor’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.36M Sell
17,141
-170,147
-91% -$33.1M 0.02% 186
2025
Q4 		$32.5M Sell
187,288
-29,416
-14% -$5.36M 0.16% 111
2025
Q3 		$41.3M Sell
216,704
-64,335
-23% -$11.4M 0.21% 101
2025
Q2 		$50.5M Sell
281,039
-33,818
-11% -$5.87M 0.26% 88
2025
Q1 		$53.3M Buy
314,857
+43,299
+16% +$7.11M 0.27% 83
2024
Q4 		$41M Buy
271,558
+30,488
+13% +$4.74M 0.22% 83
2024
Q3 		$37.4M Buy
241,070
+15,739
+7% +$2.35M 0.19% 89
2024
Q2 		$30.8M Sell
225,331
-2,523
-1% -$346K 0.17% 88
2024
Q1 		$30.3M Buy
227,854
+14,903
+7% +$1.93M 0.17% 86
2023
Q4 		$29.4M Buy
212,951
+29,469
+16% +$3.87M 0.18% 82
2023
Q3 		$22.4M Sell
183,482
-7,265
-4% -$968K 0.14% 92
2023
Q2 		$26.8M Buy
190,747
+15,701
+9% +$2.16M 0.16% 85
2023
Q1 		$24.8M Buy
175,046
+11,312
+7% +$1.62M 0.13% 88
2022
Q4 		$25.6M Buy
163,734
+12,891
+9% +$1.85M 0.16% 77
2022
Q3 		$18.5M Buy
150,843
+5,892
+4% +$776K 0.12% 84
2022
Q2 		$19.3M Buy
144,951
+56,520
+64% +$7.7M 0.13% 85
2022
Q1 		$12.1M Sell
88,431
-32,157
-27% -$4.48M 0.09% 100
2021
Q4 		$20.9M Buy
120,588
+5,771
+5% +$878K 0.12% 84
2021
Q3 		$16.7M Buy
114,817
+352
+0.3% +$51.5K 0.1% 90
2021
Q2 		$15.1M Sell
114,465
-3,683
-3% -$482K 0.09% 90
2021
Q1 		$15.2M Buy
118,148
+2,602
+2% +$321K 0.1% 92
2020
Q4 		$13.8M Buy
115,546
+2,040
+2% +$249K 0.09% 92
2020
Q3 		$13M Sell
113,506
-2,622
-2% -$310K 0.09% 89
2020
Q2 		$13.2M Sell
116,128
-1,555
-1% -$165K 0.1% 88
2020
Q1 		$9.45M Buy
117,683
+543
+0.5% +$56.2K 0.08% 99
2019
Q4 		$12.5M Buy
117,140
+15,631
+15% +$1.63M 0.09% 98
2019
Q3 		$10.9M Buy
101,509
+16,862
+20% +$1.73M 0.08% 102
2019
Q2 		$8.62M Buy
84,647
+6,724
+9% +$646K 0.06% 110
2019
Q1 		$7.01M Buy
77,923
+18,849
+32% +$1.63M 0.06% 103
2018
Q4 		$4.92M Buy
59,074
+20,875
+55% +$1.96M 0.05% 111
2018
Q3 		$4.12M Sell
38,199
-7,265
-16% -$797K 0.05% 137
2018
Q2 		$5M Buy
45,464
+10,573
+30% +$1.1M 0.05% 119
2018
Q1 		$3.5M Buy
34,891
+926
+3% +$94.8K 0.04% 148
2017
Q4 		$3.35M Buy
33,965
+8,891
+35% +$843K 0.03% 154
2017
Q3 		$2.35M Buy
25,074
+4,367
+21% +$464K 0.03% 183
2017
Q2 		$2.3M Buy
20,707
+4,195
+25% +$444K 0.03% 178
2017
Q1 		$1.62M Buy
16,512
+409
+3% +$39K 0.02% 203
2016
Q4 		$1.48M Buy
16,103
+1,041
+7% +$89.7K 0.02% 208
2016
Q3 		$1.27M Buy
15,062
+687
+5% +$57.7K 0.02% 209
2016
Q2 		$1.17M Buy
14,375
+1,163
+9% +$88.6K 0.02% 213
2016
Q1 		$944K Buy
+13,212
New +$886K 0.01% 231

Other funds holding DGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
EIG
EdgePoint Investment Group Toronto, Ontario, Canada $12.5B AUM 31.7% 1-Year Est. Return

Bahl & Gaynor's DGX Position: Q1 2026 in Review

Bahl & Gaynor reduced its Quest Diagnostics (DGX) stake by 91% in Q1 2026, selling an estimated $33.1M and leaving 17,141 shares worth $3.36M. The position accounts for 0.02% of the portfolio, ranked #186.

Bahl & Gaynor first reported a position in DGX in Q1 2016 and has held it in 41 quarters since. The position peaked at $53.3M in Q1 2025. 1,066 funds tracked by Wall St. Rank hold DGX as of Q1 2026.

  • Bahl & Gaynor held 17,141 shares of Quest Diagnostics worth $3.36M as of Q1 2026.
  • Bahl & Gaynor sold 170,147 Quest Diagnostics shares in Q1 2026, an estimated $33.1M.
  • Quest Diagnostics made up 0.02% of Bahl & Gaynor's portfolio in Q1 2026, its #186 holding.
  • Bahl & Gaynor first reported a position in Quest Diagnostics in Q1 2016 and has held it in 41 quarters since.
  • Bahl & Gaynor's Quest Diagnostics position peaked at $53.3M in Q1 2025.
  • 1,066 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2026.

Based on Bahl & Gaynor's 13F filing for Q1 2026, filed 7 May 2026.